Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays.

Eckstein M, Sailer V, Nielsen BS, Wittenberg T, Wiesmann V, Lieb V, Nolte E, Hartmann A, Kristiansen G, Wernert N, Wullich B, Taubert H, Wach S; German Prostate Cancer Consortium (DPKK).

Lab Invest. 2019 Jun 11. doi: 10.1038/s41374-019-0251-8. [Epub ahead of print]

PMID:
31186527
2.

Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma.

Kahlmeyer A, Stöhr CG, Hartmann A, Goebell PJ, Wullich B, Wach S, Taubert H, Erlmeier F.

J Clin Med. 2019 May 24;8(5). pii: E743. doi: 10.3390/jcm8050743.

3.

[The 16th DPKK annual conference "Urology meets Pathology"].

Taubert H, Becker C, Füssel S, Seitz G, Kristiansen G, Wach S, Wullich B.

Urologe A. 2019 Jun;58(6):686-689. doi: 10.1007/s00120-019-0941-2. German. No abstract available.

PMID:
31069452
4.

sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro.

Tsaur I, Hüsch T, Jüngel E, Schneider F, Schneider M, Haferkamp A, Thomas C, Lieb V, Wach S, Taubert H, Chun FK, Blaheta RA.

Urol Oncol. 2019 Jun;37(6):355.e1-355.e9. doi: 10.1016/j.urolonc.2019.03.001. Epub 2019 Apr 18.

PMID:
31005422
5.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany.

Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

PMID:
30988029
6.

Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo.

Wach S, Brandl M, Borchardt H, Weigelt K, Lukat S, Nolte E, Al-Janabi O, Hart M, Grässer F, Giedl J, Jung R, Stöhr R, Hartmann A, Lieb V, Höbel S, Peters A, Stäubert C, Wullich B, Taubert H, Aigner A.

Mol Ther Nucleic Acids. 2019 Jun 7;16:272-283. doi: 10.1016/j.omtn.2019.02.020. Epub 2019 Feb 27.

7.

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts.

Sikic D, Wirtz RM, Wach S, Dyrskjøt L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B.

Transl Oncol. 2019 Apr;12(4):661-668. doi: 10.1016/j.tranon.2019.01.005. Epub 2019 Mar 2.

8.

Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients.

Stöhr CG, Steffens S, Polifka I, Jung R, Kahlmeyer A, Ivanyi P, Weber F, Hartmann A, Wullich B, Wach S, Taubert H.

Sci Rep. 2019 Feb 11;9(1):1741. doi: 10.1038/s41598-018-38254-3.

9.

Role of androgen receptor splice variants, their clinical relevance and treatment options.

Wach S, Taubert H, Cronauer M.

World J Urol. 2019 Jan 19. doi: 10.1007/s00345-018-02619-0. [Epub ahead of print]

PMID:
30659302
10.

Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients.

Eckstein M, Jung R, Weigelt K, Sikic D, Stöhr R, Geppert C, Agaimy A, Lieb V, Hartmann A, Wullich B, Wach S, Taubert H.

Sci Rep. 2018 Dec 6;8(1):17693. doi: 10.1038/s41598-018-35637-4.

11.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

PMID:
30528808
12.

Expression of GP88 (progranulin) in serum of prostate cancer patients is associated with Gleason scores and overall survival.

Greither T, Fischer K, Theil G, Marcou M, Holzhausen HJ, Weigelt K, Serrero G, Hicks D, Yue B, Fornara P, Wullich B, Taubert H, Wach S, Lieb V.

Cancer Manag Res. 2018 Oct 5;10:4173-4180. doi: 10.2147/CMAR.S172069. eCollection 2018.

13.

Cytotoxicity of AMANTADIG - a semisynthetic digitoxigenin derivative - alone and in combination with docetaxel in human hormone-refractory prostate cancer cells and its effect on Na+/K+-ATPase inhibition.

Silva IT, Munkert J, Nolte E, Schneider NFZ, Rocha SC, Ramos ACP, Kreis W, Braga FC, de Pádua RM, Taranto AG, Cortes V, Barbosa LA, Wach S, Taubert H, Simões CMO.

Biomed Pharmacother. 2018 Nov;107:464-474. doi: 10.1016/j.biopha.2018.08.028. Epub 2018 Aug 11.

PMID:
30107342
14.

[15th annual conference of the DPKK : Molecular analysis in diagnosis and treatment].

Taubert H, Becker C, Borkowetz A, Seitz G, Kristiansen G, Wach S, Wullich B.

Urologe A. 2018 Aug;57(8):966-968. doi: 10.1007/s00120-018-0710-7. German. No abstract available.

PMID:
29934648
15.

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13.

16.

Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients.

Lieb V, Weigelt K, Scheinost L, Fischer K, Greither T, Marcou M, Theil G, Klocker H, Holzhausen HJ, Lai X, Vera J, Ekici AB, Horninger W, Fornara P, Wullich B, Taubert H, Wach S.

Oncotarget. 2017 Dec 30;9(12):10402-10416. doi: 10.18632/oncotarget.23781. eCollection 2018 Feb 13.

17.

Diagnostic potential of major and trace elements in the serum of bladder cancer patients.

Wach S, Weigelt K, Michalke B, Lieb V, Stoehr R, Keck B, Hartmann A, Wullich B, Taubert H, Chaudhri A.

J Trace Elem Med Biol. 2018 Mar;46:150-155. doi: 10.1016/j.jtemb.2017.12.010. Epub 2017 Dec 28.

PMID:
29413105
18.

Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma.

Bellut J, Bertz S, Nolte E, Stöhr C, Polifka I, Lieb V, Herrmann E, Jung R, Hartmann A, Wullich B, Taubert H, Wach S.

Sci Rep. 2017 Nov 27;7(1):16424. doi: 10.1038/s41598-017-16144-4.

19.

Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.

Sikic D, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ, Kahlmeyer A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J; Bridge Consortium.

PLoS One. 2017 Jun 20;12(6):e0179602. doi: 10.1371/journal.pone.0179602. eCollection 2017.

20.

Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.

Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG, Mogensen K, Beukers W, Marquez M, Segersten U, Høyer S, Ulhøi BP, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic C, Simic T, Junker K, Harving N, Petersen AC, Jensen JB, Keck B, Grimm MO, Horstmann M, Maurer T, Steyerberg EW, Zwarthoff EC, Real FX, Malats N, Malmström PU, Ørntoft TF.

Eur Urol. 2017 Sep;72(3):461-469. doi: 10.1016/j.eururo.2017.05.040. Epub 2017 Jun 2.

PMID:
28583312
21.

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.

Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stöhr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W.

Transl Oncol. 2017 Jun;10(3):340-345. doi: 10.1016/j.tranon.2017.01.013. Epub 2017 Mar 22.

22.

Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls.

Goebel S, Kehlen A, Bluemke K, Altermann W, Schlaf G, Fischer K, Fornara P, Wullich B, Wach S, Taubert H.

Cancer Immunol Immunother. 2017 May;66(5):565-571. doi: 10.1007/s00262-017-1957-3. Epub 2017 Feb 9.

PMID:
28184970
23.

Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target Genes.

Szczyrba J, Jung V, Beitzinger M, Nolte E, Wach S, Hart M, Sapich S, Wiesehöfer M, Taubert H, Wennemuth G, Eichner N, Stempfl T, Wullich B, Meister G, Grässer FA.

Prostate Cancer. 2017;2017:4893921. doi: 10.1155/2017/4893921. Epub 2017 Jan 5.

24.

A new semisynthetic cardenolide analog 3β-[2-(1-amantadine)- 1-on-ethylamine]-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell lines.

Nolte E, Wach S, Silva IT, Lukat S, Ekici AB, Munkert J, Müller-Uri F, Kreis W, Oliveira Simões CM, Vera J, Wullich B, Taubert H, Lai X.

Oncotarget. 2017 Feb 14;8(7):11676-11691. doi: 10.18632/oncotarget.14644.

25.

Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.

Luedeke M, Rinckleb AE, FitzGerald LM, Geybels MS, Schleutker J, Eeles RA, Teixeira MR, Cannon-Albright L, Ostrander EA, Weikert S, Herkommer K, Wahlfors T, Visakorpi T, Leinonen KA, Tammela TLJ, Cooper CS, Kote-Jarai Z, Edwards S, Goh CL, McCarthy F, Parker C, Flohr P, Paulo P, Jerónimo C, Henrique R, Krause H, Wach S, Lieb V, Rau TT, Vogel W, Kuefer R, Hofer MD, Perner S, Rubin MA, Agarwal AM, Easton DF, Al Olama AA, Benlloch S; PRACTICAL consortium, Hoegel J, Stanford JL, Maier C.

Hum Mol Genet. 2016 Dec 15;25(24):5490-5499. doi: 10.1093/hmg/ddw349.

26.

Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer.

Grampp S, Platt JL, Lauer V, Salama R, Kranz F, Neumann VK, Wach S, Stöhr C, Hartmann A, Eckardt KU, Ratcliffe PJ, Mole DR, Schödel J.

Nat Commun. 2016 Oct 24;7:13183. doi: 10.1038/ncomms13183.

27.

Cabazitaxel operates anti-metastatic and cytotoxic via apoptosis induction and stalls brain tumor angiogenesis.

Ghoochani A, Hatipoglu Majernik G, Sehm T, Wach S, Buchfelder M, Taubert H, Eyupoglu IY, Savaskan N.

Oncotarget. 2016 Jun 21;7(25):38306-38318. doi: 10.18632/oncotarget.9439.

28.

HLA-E expression and its clinical relevance in human renal cell carcinoma.

Seliger B, Jasinski-Bergner S, Quandt D, Stoehr C, Bukur J, Wach S, Legal W, Taubert H, Wullich B, Hartmann A.

Oncotarget. 2016 Oct 11;7(41):67360-67372. doi: 10.18632/oncotarget.11744.

29.

Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.

Bertz S, Wach S, Taubert H, Merten R, Krause FS, Schick S, Ott OJ, Weigert E, Dworak O, Rödel C, Fietkau R, Wullich B, Keck B, Hartmann A.

Virchows Arch. 2016 Sep;469(3):339-44. doi: 10.1007/s00428-016-1986-x. Epub 2016 Jul 8.

PMID:
27392930
30.

How Octogenarians with Bladder Cancer Are Treated in a Maximum-Care Hospital: The Real-Life Experience.

Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Lieb V, Krause FS, Merten R, Ott O, Fietkau R, Wullich B, Keck B.

Urol Int. 2017;98(3):262-267. doi: 10.1159/000447361. Epub 2016 Jul 5.

PMID:
27376673
31.

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L.

Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16.

32.

Hepatocyte differentiation markers in adenocarcinoma of the prostate: hepatocyte paraffin 1 but not arginase-1 is specifically expressed in a subset of prostatic adenocarcinoma.

Giedl J, Büttner-Herold M, Wach S, Wullich B, Hartmann A, Agaimy A.

Hum Pathol. 2016 Sep;55:101-7. doi: 10.1016/j.humpath.2016.04.016. Epub 2016 May 14.

PMID:
27184483
33.

Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma.

Jasinski-Bergner S, Reches A, Stoehr C, Massa C, Gonschorek E, Huettelmaier S, Braun J, Wach S, Wullich B, Spath V, Wang E, Marincola FM, Mandelboim O, Hartmann A, Seliger B.

Oncotarget. 2016 May 3;7(18):26866-78. doi: 10.18632/oncotarget.8567.

34.

Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients.

Stoehr CG, Stoehr R, Wenners A, Hartmann A, Bertz S, Spath V, Walter B, Junker K, Moch H, Hinze R, Denzinger S, Bond EE, Bond GL, Bluemke K, Weigelt K, Lieb V, Nolte E, Fornara P, Wullich B, Taubert H, Wach S.

Oncogenesis. 2016 Feb 29;5:e205. doi: 10.1038/oncsis.2016.15.

35.

MiRNA-21 Expression Decreases from Primary Tumors to Liver Metastases in Colorectal Carcinoma.

Feiersinger F, Nolte E, Wach S, Rau TT, Vassos N, Geppert C, Konrad A, Merkel S, Taubert H, Stürzl M, Croner RS.

PLoS One. 2016 Feb 4;11(2):e0148580. doi: 10.1371/journal.pone.0148580. eCollection 2016.

36.

The New Semisynthetic Cardenolide Analog 3β-[2-(1-Amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) Efficiently Suppresses Cell Growth in Human Leukemia and Urological Tumor Cell Lines.

Nolte E, Sobel A, Wach S, Hertlein H, Ebert N, Müller-Uri F, Slany R, Taubert H, Wullich B, Kreis W.

Anticancer Res. 2015 Oct;35(10):5271-5.

PMID:
26408686
37.

Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma.

Jasinski-Bergner S, Stoehr C, Bukur J, Massa C, Braun J, Hüttelmaier S, Spath V, Wartenberg R, Legal W, Taubert H, Wach S, Wullich B, Hartmann A, Seliger B.

Oncoimmunology. 2015 Mar 2;4(6):e1008805. eCollection 2015 Jun.

38.

Female Gender Is an Age-dependent Negative Prognostic Factor for Patients with Upper Tract Urothelial Carcinoma.

Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Goebell PJ, Schick S, Olbert P, Huber J, Wullich B, Keck B.

Anticancer Res. 2015 Jul;35(7):4277-81.

PMID:
26124390
39.

miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis.

Benderska N, Dittrich AL, Knaup S, Rau TT, Neufert C, Wach S, Fahlbusch FB, Rauh M, Wirtz RM, Agaimy A, Srinivasan S, Mahadevan V, Rümmele P, Rapti E, Gazouli M, Hartmann A, Schneider-Stock R.

Inflamm Bowel Dis. 2015 Sep;21(9):2039-51. doi: 10.1097/MIB.0000000000000453.

40.

Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients.

Taubert H, Wach S, Jung R, Pugia M, Keck B, Bertz S, Nolte E, Stoehr R, Lehmann J, Ohlmann CH, Stöckle M, Wullich B, Hartmann A.

Mol Med. 2015 May 13;21:371-80. doi: 10.2119/molmed.2014.00250.

41.

mRNA expression levels of hypoxia-induced and stem cell-associated genes in human glioblastoma.

Bache M, Rot S, Keßler J, Güttler A, Wichmann H, Greither T, Wach S, Taubert H, Söling A, Bilkenroth U, Kappler M, Vordermark D.

Oncol Rep. 2015 Jun;33(6):3155-61. doi: 10.3892/or.2015.3932. Epub 2015 Apr 27.

PMID:
25963717
42.

The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.

Wach S, Al-Janabi O, Weigelt K, Fischer K, Greither T, Marcou M, Theil G, Nolte E, Holzhausen HJ, Stöhr R, Huppert V, Hartmann A, Fornara P, Wullich B, Taubert H.

Int J Cancer. 2015 Sep 15;137(6):1406-16. doi: 10.1002/ijc.29505. Epub 2015 Mar 18.

43.

Comparative genomic hybridization shows complex genomic changes of plasmacytoid urothelial carcinoma.

Keck B, Ellmann C, Stoehr R, Weigelt K, Goebell PJ, Kunath F, Taubert H, Hartmann A, Wullich B, Wach S.

Urol Oncol. 2014 Nov;32(8):1234-9. doi: 10.1016/j.urolonc.2014.06.016. Epub 2014 Jul 30.

PMID:
25087089
44.

Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.

Al-Janabi O, Taubert H, Lohse-Fischer A, Fröhner M, Wach S, Stöhr R, Keck B, Burger M, Wieland W, Erdmann K, Wirth MP, Wullich B, Baretton G, Magdolen V, Kotzsch M, Füssel S.

Biomed Res Int. 2014;2014:972587. doi: 10.1155/2014/972587. Epub 2014 Apr 29.

45.

Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients.

Keck B, Wach S, Taubert H, Zeiler S, Ott OJ, Kunath F, Hartmann A, Bertz S, Weiss C, Hönscheid P, Schellenburg S, Rödel C, Baretton GB, Sauer R, Fietkau R, Wullich B, Krause FS, Datta K, Muders MH.

Int J Cancer. 2015 Jan 15;136(2):443-51. doi: 10.1002/ijc.28987. Epub 2014 Jun 12.

46.

High coexpression of CCL2 and CX3CL1 is gender-specifically associated with good prognosis in soft tissue sarcoma patients.

Kehlen A, Greither T, Wach S, Nolte E, Kappler M, Bache M, Holzhausen HJ, Lautenschläger C, Göbel S, Würl P, Immel UD, Agaimy A, Wullich B, Taubert H.

Int J Cancer. 2014 Nov 1;135(9):2096-106. doi: 10.1002/ijc.28867. Epub 2014 Apr 4.

47.

Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study.

Rogler A, Hoja S, Giedl J, Ekici AB, Wach S, Taubert H, Goebell PJ, Wullich B, Stöckle M, Lehmann J, Petsch S, Hartmann A, Stoehr R.

BMC Cancer. 2014 Mar 20;14:214. doi: 10.1186/1471-2407-14-214.

48.

Piwi-like 1 and 4 gene transcript levels are associated with clinicopathological parameters in renal cell carcinomas.

Al-Janabi O, Wach S, Nolte E, Weigelt K, Rau TT, Stöhr C, Legal W, Schick S, Greither T, Hartmann A, Wullich B, Taubert H.

Biochim Biophys Acta. 2014 May;1842(5):686-90. doi: 10.1016/j.bbadis.2014.01.014. Epub 2014 Feb 7.

49.

Micro-a-fluidics ELISA for rapid CD4 cell count at the point-of-care.

Wang S, Tasoglu S, Chen PZ, Chen M, Akbas R, Wach S, Ozdemir CI, Gurkan UA, Giguel FF, Kuritzkes DR, Demirci U.

Sci Rep. 2014 Jan 22;4:3796. doi: 10.1038/srep03796.

50.

Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing.

Hart M, Nolte E, Wach S, Szczyrba J, Taubert H, Rau TT, Hartmann A, Grässer FA, Wullich B.

Mol Cancer Res. 2014 Feb;12(2):250-63. doi: 10.1158/1541-7786.MCR-13-0230. Epub 2013 Dec 13.

Supplemental Content

Support Center